Mass production of iPSC-derived platelets toward the clinical application.

"Declaration of competing interest K.E. was the founder of Megakaryon, which conducted a clinical trial using allogenic iPSC-PLTs (but K.E. has no stock of Megakaryon). Otsuka Pharmaceutical Co. Ltd., Megakaryon Co., and Satake Multimix Co. provided collaborating project fundings."

"The authors thank the members of the Eto laboratory (Center for iPS Cell Research and Application [CiRA], Kyoto University) and Drs. Naoshi Sugimoto and Peter Karagiannis for reading the manuscript. This work was supported in part by the Regenerative Innovation grant (JP20bm0704051, JP21bm0704051 and JP22bm0704051) and Core research center for next-generation medicine utilizing cell and gene therapy grant (JP23bm1323001) from AMED, the CiRA Foundation Fund, and a grant-in-aid for scientific research (KIBAN S, 21H05047) from the 10.13039/501100001691Japan Society for the Promotion of Science (JSPS)."